- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01988857
Safety of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Healthy Vietnamese Children
Safety and Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix™) in Healthy Vietnamese Children
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
A phase III, single-group, open-label study of GSK Biologicals' vaccine BoostrixTM administered as a booster vaccine dose in healthy Vietnamese children aged 6-10 years. A single booster dose of BoostrixTM will be administered at Visit 1 (Day 0) and subjects will be observed until Visit 2 (Day 30). Safety will be assessed in terms of solicited adverse events (during 4 days post vaccination), unsolicited adverse events (during 31 days post vaccination) and serious adverse event (during the trial period).
This protocol summary was updated following an administrative change of adding the EudraCT number to this study.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 3
Kontakter och platser
Studieorter
-
-
-
Hanoi, Vietnam, 084
- GSK Investigational Site
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Subjects who the investigator believes that their parent(s)/Legally Acceptable Representative(s) [LAR(s)] can and will comply with the requirements of the protocol.
- A male or female between, and including, 6 and 10 years of age at the time of the vaccination.
- Written informed consent obtained from the parent(s)/LAR(s) of the subject.
- Written informed assent to be obtained from the subject in addition to the informed consent signed by the parent(s)/LAR(s), as required by local regulations.
- Healthy subjects as established by medical history and clinical examination before entering into the study.
- Subjects who have previously completed their routine vaccinations against diphtheria, tetanus and pertussis diseases according to the local recommended vaccination schedule at that time and have not received the vaccine in the last two years prior to study dose administration.
- Female subjects of non-childbearing potential may be enrolled in the study.
Female subjects of childbearing potential may be enrolled in the study, if the subject:
- has practiced abstinence or adequate contraception for 30 days prior to vaccination, and
- has a negative pregnancy test on the day of vaccination, and
- has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.
Exclusion Criteria:
- Child in care.
- Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the booster dose of study vaccine, or planned use during the study period.
- Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to vaccination. Inhaled and topical steroids are allowed.
- Administration of a vaccine not foreseen by the study protocol within 30 days prior to the booster vaccine dose, or planned administration during the study period.
- Administration of immunoglobulins and/or any blood products within the three months preceding Visit 1 or planned administration during the study period.
- Occurrence of transient thrombocytopenia or neurological complications following an earlier immunisation against diphtheria and/or tetanus.
- Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
- A history of previous or intercurrent diphtheria, tetanus or pertussis disease.
- History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.
- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
- Major congenital defects or serious chronic illness.
- Acute disease and/or fever at the time of enrollment.
- Pregnant or lactating female.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: dTpa Group
|
Single-dose administered intramuscularly in the deltoid region of non-dominant arm.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Numbers of Subjects With Any and Grade 3 Solicited Local Symptoms
Tidsram: Within 4 days (Days 0-3) post vaccination period
|
Assessed solicited local symptoms were pain, redness and swelling.
Any = occurrence of the symptom regardless of intensity grade.
Grade 3 pain = pain that prevented normal activity.
Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
Relationship analysis was not performed.
|
Within 4 days (Days 0-3) post vaccination period
|
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
Tidsram: Within 4 days (Days 0-3) post vaccination period
|
Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache and temperature [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)].
Any = occurrence of the symptom regardless of intensity grade.
Grade 3 symptom = symptom that prevented normal activity.
Grade 3 fever = fever > 39.0 °C.
Related = symptom assessed by the investigator as related to the vaccination.
|
Within 4 days (Days 0-3) post vaccination period
|
Number of Subjects With Unsolicited Adverse Events (AEs)
Tidsram: Within 31 days (Days 0-30) post vaccination period
|
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
|
Within 31 days (Days 0-30) post vaccination period
|
Number of Subjects With Serious Adverse Events (SAEs)
Tidsram: During the entire study period (From Day 0 to Day 30)
|
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
|
During the entire study period (From Day 0 to Day 30)
|
Samarbetspartners och utredare
Sponsor
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 115739
- 2013-003859-37 (EudraCT-nummer)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Tidsram för IPD-delning
Kriterier för IPD Sharing Access
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
- ICF
- CSR
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Stelkramp
-
Changchun BCHT Biotechnology Co.The First Affiliated Hospital of Yunnan University of Traditional Chinese... och andra samarbetspartnersHar inte rekryterat ännu
-
Women and Infants Hospital of Rhode IslandHar inte rekryterat ännuVaccinexponering under graviditet | Tdap - Tetanus, difteri och acellulär pertussisvaccination | Icke-födande partnervaccination under graviditet
-
National Institute of Allergy and Infectious Diseases...AvslutadKikhosta | Stelkramp | Difteri | Immunisering mot difteri | Tetanus immunisering | Clostridium Difficile-immuniseringMali
-
Serum Institute of India Pvt. Ltd.RekryteringHepatit B-vaccination | Immunisering mot difteri | Tetanus immunisering | Immunisering av pertussis | Immunisering av Haemophilus Influenzae Typ B | PoliovaccinationBangladesh, Indien
-
Children's Mercy Hospital Kansas CityUniversity of Kansas Medical Center; Midwest Cancer AllianceAvslutadKommunikation | Meningit, meningokocker | Tillfredsställelse | Mänskligt papillomvirus | Tdap - Tetanus, difteri och acellulär pertussisvaccinationFörenta staterna
-
Sanofi Pasteur, a Sanofi CompanyAvslutadImmunisering av pertussis | Immunisering mot difteri | Tetanus immunisering | PoliomyelitvaccinSydafrika
-
Sanofi Pasteur, a Sanofi CompanyAvslutadImmunisering av pertussis | Immunisering mot difteri | Tetanus immunisering | Immunisering mot pneumokocker | Hepatit B-vaccination | Poliovaccination | Immunisering av Haemophilus Influenzae Typ B | Immunisering mot rotavirusThailand
-
Sanofi Pasteur, a Sanofi CompanyAvslutadImmunisering av pertussis | Immunisering mot difteri | Tetanus immunisering | Immunisering mot pneumokocker | Hepatit B-vaccination | Haemophilus Influenzae Typ b Immunisering | Poliovaccination | Vaccination mot mässling | Immunisering av röda hund | Varicellavaccination | Immunisering mot påssjukaFörenta staterna, Kanada, Honduras, Puerto Rico
Kliniska prövningar på Boostrix™
-
GlaxoSmithKlineAvslutadStelkramp | Difteri | Acellulär PertussisBelgien
-
GlaxoSmithKlineAvslutadStelkramp | Difteri | Acellulär Pertussis | Difteri-stelkramp-acellulära pertussisvaccinerAustralien
-
GlaxoSmithKlineAvslutadStelkramp | Difteri | Acellulär PertussisFörenta staterna
-
GlaxoSmithKlineAvslutadDifteri-stelkramp-acellulära pertussisvaccinerFinland, Australien, Spanien, Italien, Kanada, Tjeckien
-
GlaxoSmithKlineAvslutadStelkramp | Difteri | Acellulär Pertussis | Difteri-stelkramp-acellulära pertussisvaccinerFörenta staterna
-
GlaxoSmithKlineAvslutadStelkramp | Difteri | Acellulär PertussisFörenta staterna
-
DBV TechnologiesUniversity Hospital, GenevaAvslutad
-
GlaxoSmithKlineAvslutadStelkramp | Difteri | Acellulär PertussisMexiko, Chile
-
St. Justine's HospitalMinistere de la Sante et des Services SociauxAvslutad
-
University of Prince Edward IslandThe Queen Elizabeth HospitalAvslutad